Clinical Pharmacology and Biopharmaceutics Review

I. Project Identification

NDA number/serial number 20,038/SE8-028-PM
Submission date February 7, 2003
Drug name Fludara
Generic name Fludarabine
Dosage form lyophilized powder for IV injection
Sponsor Berlex Laboratories
15049 San Pablo Avenue
Richmond, CA 94804-0099
Reviewer Anne Zajicek, M.D., Pharm.D.
Submission Type NDA-Supplement

II. Executive Summary

The applicant submitted the results of two clinical studies of fludarabine in children with relapsed malignancies. Study CCG-097 was a Phase 1 pharmacokinetic study of 23 children with relapsed acute leukemias (n=18) and solid tumors (n=5) who were randomized to receive one of six increasing bolus + 5 day infusion regimens. The pharmacokinetics of fludarabine in these children was markedly different from that reported in adult studies. Mean clearance in the children was 0.61 L/hr/m², compared with 8.7 and 4.1 L/hr/m² in two adult studies. Half-life and volume of distribution were similar to adult values (12.4 vs 10.4 hours, and 10.8 vs 7.5 L/m² respectively). The explanation of this difference is unclear. Study CCG-0895 was a Phase 1/2 study combining bolus + 2 day infusion fludarabine, followed by a 3 day infusion of increasing dose cytarabine in children with relapsed acute leukemias. There were three children with evaluable data; their clearance values were similar to those seen in CCG-097, ranging from 0.44-2.15 L/h/m².

No labeling changes for pediatric indications or dosing will be made at this time due to inadequate efficacy data generated in the study report.
Anne Zajicek, M.D., Pharm.D.
Medical Officer, Clinical Pharmacology Reviewer
DPE1

N.A.M. Atiquur Rahman, Ph.D.
Team Leader
DPE1

CC: NDA 20,038/SE8-028
HFD-150 Division File
HFD-150 DPease
HFD-150 MCOhen, JJohnson
HFD-860 MMehta, CSahajwalla, ARahman, AZajicek
CDR Biopharmaceutics
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Atiqur Rahman
7/28/03 02:43:44 PM

Anne Zajicek
7/28/03 02:47:35 PM